Parameter | Value | Source |
---|---|---|
Population distribution | Â | Â |
Birth cohort | 550,000 | |
20-39 years age group | 8,770,937 | |
40-64 years group | 5,536,238 | |
≥ 65 years group | 1,051,371 | |
Life expectancy at birth (years) | 74.2 | [30] |
PCV7 vaccine coverage | 495,000 | 90% of birth cohort [12] |
PCV7 vaccine compliance | 100% | Â |
Pneumococcal disease incidence | Â | Â |
S. pneumonia isolated | 100% | Â |
Unspecified meningitis and bacteraemia | 36% | [24] |
All cause pneumonia | 30% | [23] |
Paediatric fatality rate | Â | Â |
Meningitis | 0.2 | [31] |
Bacteraemia | 0.1 | [31] |
All cause pneumonia | 0% | [31] |
Otitis media | 0% | [31] |
Adult fatality rate | Â | Â |
Meningitis | 9.0% | [32] |
Bacteraemia | 4.6% | [32] |
All cause pneumonia | 0.17% | [32] |
Otitis media | 0% | [32] |
PCV7 serotype coverage | 66.7% | [28] |
PCV7 efficacy in infants | Â | Â |
Pneumococcal meningitis | 97.4% | [27] |
Pneumococcal bacteraemia | 97.4% | [27] |
All cause pneumonia | 6% | [27] |
Otitis media | 7% | [27] |
PCV7 efficacy decline over time (efficacy waning) | Â | Â |
≤ 5 years post-vaccination | 1% p.a. | [22] |
6-10 years post-vaccination | 3% p.a. | [22] |
Reduction on IPD in adults (herd effects) | Â | Â |
20-39 years group | 32% | [29] |
40-64 years group | 8% | [29] |
≥ 65 years group | 18% | [29] |